Trials / Terminated
TerminatedNCT01476657
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 210 (actual)
- Sponsor
- SecuraBio · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, maximum tolerated dose and pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IPI-145 (duvelisib) | Oral Twice A Day (BID) Dosing |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2016-12-01
- Completion
- 2017-01-01
- First posted
- 2011-11-22
- Last updated
- 2021-03-17
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01476657. Inclusion in this directory is not an endorsement.